Study on Predicting Response of Recurrent Glioblastoma to Apatinib
Latest Information Update: 24 Jul 2023
At a glance
- Drugs Rivoceranib (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic
- 20 Jul 2023 Status changed from active, no longer recruiting to completed.
- 18 Apr 2023 Planned End Date changed from 1 Dec 2022 to 31 Jul 2023.
- 18 Apr 2023 Status changed from recruiting to active, no longer recruiting.